Resveratrol-salicylate derivatives as selective DNMT3 inhibitors and anticancer agents

References

• Fulda S. Resveratrol and derivatives for the prevention and treatment of cancer. Drug Discov Today 2010;15:757–65
   PubMed Web of Science ®Google Scholar
• Athar M, Back JH, Kopelovich L, et al. Multiple molecular targets of resveratrol: anti-carcinogenic mechanisms. Arch Biochem Biophys 2009;486:95–102
   PubMed Web of Science ®Google Scholar
• Athar M, Back JH, Tang X, et al. Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol Appl Pharmacol 2007;224:274–83
   PubMed Web of Science ®Google Scholar
• Goswami SK, Das DK. Resveratrol and chemoprevention. Cancer Lett 2009;284:1–6
   PubMed Web of Science ®Google Scholar
• Kundu JK, Surh Y-J. Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives. Cancer Lett 2008;269:243–61
   PubMed Web of Science ®Google Scholar
• Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006;5:493–506
   PubMed Web of Science ®Google Scholar
• Signorelli P, Ghidoni R. Resveratrol as an anticancer nutrient: molecular basis, open questions and promises. J Nutr Biochem 2005;16:449–66
   PubMed Web of Science ®Google Scholar
• Sengottuvelan M, Senthilkumar R, Nalini N. Modulatory influence of dietary resveratrol during different phases of 1,2-dimethylhydrazine induced mucosal lipid-peroxidation, antioxidant status and aberrant crypt foci development in rat colon carcinogenesis. BBA Gen Subjects 2006;1760:1175–83
   PubMed Web of Science ®Google Scholar
• Das S, Das DK. Resveratrol: a therapeutic promise for cardiovascular diseases. Recent Pat Cardiovasc Drug Discov 2007;2:133–8
   PubMedGoogle Scholar
• Gehm BD, Levenson AS, Liu H, et al. Estrogenic effects of resveratrol in breast cancer cells expressing mutant and wild-type estrogen receptors: role of AF-1 and AF-2. J Steroid Biochem Mol Biol 2004;88:223–34
   PubMed Web of Science ®Google Scholar
• Juan ME, Alfaras I, Planas JM. Colorectal cancer chemoprevention by trans-resveratrol. Pharmacol Res 2012;65:584–91
   PubMed Web of Science ®Google Scholar
• Gwak H, Haegeman G, Tsang BK, Song YS. Cancer-specific interruption of glucose metabolism by resveratrol is mediated through inhibition of Akt/GLUT1 axis in ovarian cancer cells. Mol Carcinog 2014 . [Epub ahead of print]. doi:10.1002/mc.22133
   PubMed Web of Science ®Google Scholar
• Clement MV, Hirpara JL, Chawdhury SH, Pervaiz S. Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD95 signaling-dependent apoptosis in human tumor cells. Blood 1998;92:996–1002
   PubMed Web of Science ®Google Scholar
• Tinhofer I, Bernhard D, Senfter M, et al. Resveratrol, a tumor-suppressive compound from grapes, induces apoptosis via a novel mitochondrial pathway controlled by Bcl-2. FASEB J 2001;15:1613–15
   PubMed Web of Science ®Google Scholar
• Joe AK, Liu H, Suzui M, et al. Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker expression in several human cancer cell lines. Clin Cancer Res 2002;8:893–903
   PubMed Web of Science ®Google Scholar
• Bai Y, Mao Q-Q, Qin J, et al. Resveratrol induces apoptosis and cell cycle arrest of human T24 bladder cancer cells in vitro and inhibits tumor growth in vivo. Cancer Sci 2010;101:488–93
   PubMed Web of Science ®Google Scholar
• Yin HT, Tian QZ, Guan L, et al. In vitro and in vivo evaluation of the antitumor efficiency of resveratrol against lung cancer. Asian Pac J Cancer Prev 2013;14:1703–6
   PubMed Web of Science ®Google Scholar
• Medina-Franco JL, Giulianotti MA, Welmaker GS, Houghten RA. Shifting from the single to the multitarget paradigm in drug discovery. Drug Discov Today 2013;18:495–501
   PubMed Web of Science ®Google Scholar
• Pallauf K, Giller K, Huebbe P, Rimbach G. Nutrition and healthy ageing: calorie restriction or polyphenol-rich “MediterrAsian” diet? Oxid Med Cell Longev 2013;2013:707421
   PubMed Web of Science ®Google Scholar
• Denis H, Ndlovu MN, Fuks F. Regulation of mammalian DNA methyltransferases: a route to new mechanisms. EMBO Rep 2011;12:647–56
   PubMed Web of Science ®Google Scholar
• Gnyszka A, Jastrzebski Z, Flis S. DNA methyltransferase inhibitors and their emerging role in epigenetic therapy of cancer. Anticancer Res 2013;33:2989–96
   PubMed Web of Science ®Google Scholar
• Gao J, Wang L, Xu J, et al. Aberrant DNA methyltransferase expression in pancreatic ductal adenocarcinoma development and progression. J Exp Clin Cancer Res 2013;32:86
   PubMed Web of Science ®Google Scholar
• Zhu W, Qin W, Zhang K, et al. Trans-resveratrol alters mammary promoter hypermethylation in women at increased risk for breast cancer. Nutr Cancer 2012;64:393–400
   PubMed Web of Science ®Google Scholar
• Capobianco E, Mora A, La Sala D, et al. Separate and combined effects of DNMT and HDAC inhibitors in treating human multi-drug resistant osteosarcoma HosDXR150 cell line. PLoS One 2014;9:e95596
   Google Scholar
• Flis S, Gnyszka A, Flis K. DNA methyltransferase inhibitors improve the effect of chemotherapeutic agents in SW48 and HT-29 colorectal cancer cells. PLoS One 2014;9:e92305
   PubMed Web of Science ®Google Scholar
• Sandhu R, Rivenbark AG, Coleman WB. Enhancement of chemotherapeutic efficacy in hypermethylator breast cancer cells through targeted and pharmacologic inhibition of DNMT3b. Breast Cancer Res Treat 2012;131:385–99
   PubMed Web of Science ®Google Scholar
• Kim HJ, Kim JH, Chie EK, et al. DNMT (DNA methyltransferase) inhibitors radiosensitize human cancer cells by suppressing DNA repair activity. Radiat Oncol 2012;7:39
   PubMed Web of Science ®Google Scholar
• Chen C, Pan D, Deng AM, et al. DNA methyltransferases 1 and 3B are required for hepatitis C virus infection in cell culture. Virology 2013;441:57–65
   PubMed Web of Science ®Google Scholar
• Sin-Chan P, Huang A. DNMTs as potential therapeutic targets in high-risk pediatric embryonal brain tumors. Expert Opin Ther Targets 2014;18:1103–7
   PubMed Web of Science ®Google Scholar
• Subramaniam D, Thombre R, Dhar A, Anant S. DNA methyltransferases: a novel target for prevention and therapy. Front Oncol 2014;4:80
   PubMedGoogle Scholar
• Erdmann A, Halby L, Fahy J, Arimondo PB. Targeting DNA methylation with small molecules: what's next? J Med Chem 2014;58:2569--83
   PubMed Web of Science ®Google Scholar
• Medina-Franco JL, Méndez-Lucio O, Yoo J, Dueñas A. Discovery and development of DNA methyltransferase inhibitors using in silico approaches. Drug Discov Today 2015;20:569--77
   PubMed Web of Science ®Google Scholar
• Fahy J, Jeltsch A, Arimondo PB. DNA methyltransferase inhibitors in cancer: a chemical and therapeutic patent overview and selected clinical studies. Expert Opin Ther Pat 2012;22:1427–42
   PubMed Web of Science ®Google Scholar
• Brueckner B, Boy RG, Siedlecki P, et al. Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Res 2005;65:6305–11
   PubMed Web of Science ®Google Scholar
• Fang MZ, Wang YM, Ai N, et al. Tea polyphenol (−)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res 2003;63:7563–70
   PubMed Web of Science ®Google Scholar
• Mendez-Lucio O, Tran J, Medina-Franco JL, et al. Toward drug repurposing in epigenetics: olsalazine as a hypomethylating compound active in a cellular context. Chem Med Chem 2014;9:560–5
   Web of Science ®Google Scholar
• Kuck D, Singh N, Lyko F, Medina-Franco JL. Novel and selective DNA methyltransferase inhibitors: docking-based virtual screening and experimental evaluation. Bioorg Med Chem 2010;18:822–9
   PubMed Web of Science ®Google Scholar
• Aldawsari FS, Elshenawy OH, El Gendy MA, et al. Design and synthesis of resveratrol-salicylate hybrid derivatives as CYP1A1 inhibitors. J Enzyme Inhib Med Chem 2014 . [Epub ahead of print]. doi: 10.3109/14756366.2014.979347
   PubMed Web of Science ®Google Scholar
• Qin W, Zhang K, Clarke K, et al. Methylation and miRNA effects of resveratrol on mammary tumors vs. normal tissue. Nutr Cancer 2014;66:270–7
   PubMed Web of Science ®Google Scholar
• Hemeon I, Gutierrez JA, Ho M-C, Schramm VL. Characterizing DNA methyltransferases with an ultrasensitive luciferase-linked continuous assay. Anal Chem 2011;83:4996–5004
   PubMed Web of Science ®Google Scholar
• Song J, Rechkoblit O, Bestor TH, Patel DJ. Structure of DNMT1–DNA complex reveals a role for autoinhibition in maintenance DNA methylation. Science 2011;331:1036–40
   PubMed Web of Science ®Google Scholar
• Zheng W, Ibáñez G, Wu H, et al. Sinefungin derivatives as inhibitors and structure probes of protein lysine methyltransferase SETD2. J Am Chem Soc 2012;134:18004–14
   PubMed Web of Science ®Google Scholar
• Macromdel, version 9.8. , New York, NY: Schrödinger, LLC; 2010
   Google Scholar
• Pettersen EF, Goddard TD, Huang CC, et al. UCSF Chimera – a visualization system for exploratory research and analysis. J Comput Chem 2004;25:1605–12
   PubMed Web of Science ®Google Scholar
• Morris GM, Huey R, Lindstrom W, et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 2009;30:2785–91
   PubMed Web of Science ®Google Scholar
• Chen Y, Hu F, Gao Y, et al. Design, synthesis, and evaluation of methoxylated resveratrol derivatives as potential antitumor agents. Res Chem Intermed 2013;41:2725–38
   Web of Science ®Google Scholar
• Mikeska T, Craig JM. DNA methylation biomarkers: cancer and beyond. Genes (Basel) 2014;5:821–64
   PubMed Web of Science ®Google Scholar
• Cacabelos R, Torrellas C. Epigenetic drug discovery for Alzheimer's disease. Expert Opin Drug Discov 2014;9:1059–86
   PubMed Web of Science ®Google Scholar
• Chaturvedi P, Tyagi SC. Epigenetic mechanisms underlying cardiac degeneration and regeneration. Int J Cardiol 2014;173:1–11
   PubMed Web of Science ®Google Scholar
• Stankov K, Benc D, Draskovic D. Genetic and epigenetic factors in etiology of diabetes mellitus type 1. Pediatrics 2013;132:1112–22
   PubMed Web of Science ®Google Scholar
• Ross SA. Diet and DNA methylation interactions in cancer prevention. Ann NY Acad Sci 2003;983:197–207
   PubMed Web of Science ®Google Scholar
• Medina-Franco JL, Yoo J. Docking of a novel DNA methyltransferase inhibitor identified from high-throughput screening: insights to unveil inhibitors in chemical databases. Mol Divers 2013;17:337–44
   PubMed Web of Science ®Google Scholar
• Yoo J, Choi S, Medina-Franco JL. Molecular modeling studies of the novel inhibitors of DNA methyltransferases SGI-1027 and CBC12: implications for the mechanism of inhibition of DNMTs. PLoS One 2013;8:e62152
   PubMed Web of Science ®Google Scholar
• Isakovic L, Saavedra OM, Llewellyn DB, et al. Constrained (l-)-S-adenosyl-l-homocysteine (SAH) analogues as DNA methyltransferase inhibitors. Bioorg Med Chem Lett 2009;19:2742–6
   PubMed Web of Science ®Google Scholar
• Saavedra OM, Isakovic L, Llewellyn DB, et al. SAR around (l)-S-adenosyl-l-homocysteine, an inhibitor of human DNA methyltransferase (DNMT) enzymes. Bioorg Med Chem Lett 2009;19:2747–51
   PubMed Web of Science ®Google Scholar
• Medina-Franco JL, Mendez-Lucio O, Yoo J. Rationalization of activity cliffs of a sulfonamide inhibitor of DNA methyltransferases with induced-fit docking. Int J Mol Sci 2014;15:3253–61
   PubMed Web of Science ®Google Scholar
• Kilgore JA, Du XL, Melito L, et al. Identification of DNMT1 selective antagonists using a novel scintillation proximity assay. J Biol Chem 2013;288:19673–84
   PubMed Web of Science ®Google Scholar
• Rilova E, Erdmann A, Gros C, et al. Design, synthesis and biological evaluation of 4-amino-N-(4-aminophenyl)benzamide analogues of quinoline-based SGI-1027 as inhibitors of DNA methylation. Chem Med Chem 2014;9:590–601
   Web of Science ®Google Scholar
• Suzuki T, Tanaka R, Hamada S, et al. Design, synthesis, inhibitory activity, and binding mode study of novel DNA methyltransferase 1 inhibitors. Bioorg Med Chem Lett 2010;20:1124–7
   PubMed Web of Science ®Google Scholar
• Asgatay S, Champion C, Marloie G, et al. Synthesis and evaluation of analogues of N-phthaloyl-l-tryptophan (RG108) as inhibitors of DNA methyltransferase 1. J Med Chem 2013;57:421–34
   Web of Science ®Google Scholar
• Bello M, Martinez-Archundia M, Correa-Basurto J. Automated docking for novel drug discovery. Expert Opin Drug Discov 2013;8:821–34
   PubMed Web of Science ®Google Scholar
• Kuck D, Caulfield T, Lyko F, Medina-Franco JL. Nanaomycin A selectively inhibits DNMT3B and reactivates silenced tumor suppressor genes in human cancer cells. Mol Cancer Ther 2010;9:3015–23
   PubMed Web of Science ®Google Scholar
• Sun Q, Xie Y, Wang G, Li J. Identification of genes in HepG2 cells that respond to DNA methylation and histone deacetylation inhibitor treatment. Exp Ther Med 2014;8:813–17
   PubMed Web of Science ®Google Scholar
• Costa FF, Verbisck NV, Salim AC, et al. Epigenetic silencing of the adhesion molecule ADAM23 is highly frequent in breast tumors. Oncogene 2004;23:1481–8
   PubMed Web of Science ®Google Scholar